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The Genetic Variants of Alpha-1 Antitrypsin 
Deficiency
Alpha-1 antitrypsin (AAT) as explained by Brode, Ling, and Chapman (2012) is a 
glycoprotein protease inhibitor encoded by the SERPINA1 gene on chromosome 14. 
Alpha-1 antitrypsin is synthesized in the liver and secreted into the blood. It travels to 
the lungs where it diffuses into the interstitium and the alveolar lining fluid. Here it 
inactivates neutrophil elastase, helping to protect the lungs from protease-mediated 
damage (Brode, Ling, & Chapman, 2012). 
Stoller and Brantly (2013) describe AATD as an autosomal co-dominant condition with 
over 100 variants (Stoller & Brantly, 2013). Brode, Ling, and Chapman (2012) further 
explain that not all of the variants are associated with the disease. The most common 
of these variants is the M allele. The M allele variant poses no risk for liver or lung 
disease. Most people with severe AATD are homozygous for the Z allele. The Z allele 
variant protein miss-folds and polymerizes during its production in the endoplasmic 
reticulum of hepatocytes. The abnormal polymers get trapped in the liver; reducing 
the amount of AAT released into the blood. As a result, the alveoli allows uncontrolled 
proteolytic attack and tissue destruction of the lungs. The connective tissue 
throughout the lungs is damaged, due to the increase in elastase activity. The decrease 
is AAT in the lungs places the individual at risk for lung disease. However, there has to
be environmental or other genetic factors to elicit respiratory symptoms. The buildup 
of AAT in the liver causes liver disease. The AAT causes a reaction from the 
hepatocytes including autophagy and apoptosis of hepatocytes (Brode, Ling, & 
Chapman, 2012).   
Treatment
Pini et al. (2014) research indicates that a new treatment should be developed for Z-
phenotype AATD patients. AAT is mainly produced by the hepatic cells. However, 
there is a small amount produced by the bronchial epithelial cells (BEC). 
Inflammation causes BECs to secrete Z-AAT protein and its polymers. The process 
may be involved in the pathogenesis of lung emphysema and in BEC dysfunction. A 
new therapeutic approach for such a finding could be a treatment to prevent 
polymer formation, thus blocking the destruction of the lung tissue (Pini et al., 2014).
Prolastin infusion therapy, as pointed out by Koepke et al. (2013), has been the 
treatment of choice for the past 30 years for patients with AATD-related 
emphysema. The intravenous infusions are weekly for an indefinite amount of time. 
Prolastin is an augmentation therapy using AAT from purified pooled human plasma. 
The treatment greatly reduces the sputum elastase activity and levels of leukotriene 
B4, IL-8, and myeloperoxidase. It also reduces lung consolidation caused by 
proteolytic attack and destruction of lung tissue. Currently, this is the best therapy 
available for AATD (Koepke et al., 2013).
At the VAACC Prolastin augmentation therapy is provided for veterans with AATD-
acquired COPD, when indicated. Standard medication prescribed for COPD symptom 
management would be the following: 
• Albuterol Sulfate: short-acting beta-2 adrenergic agonist bronchodilator (rescue 
inhaler) 
• Budesonide/Formoterol Fumarate Dihydrate: anti-inflammatory 
corticosteroid/long-acting β2 agonist bronchodilator (twice daily)   
• Tiotropium Bromide: long-acting anticholinergic bronchodilator (once daily)
• Montelukast:  leukotriene receptor antagonist  (once daily)
These medications provide the optimal breathing conditions for the patient. The 
VAACC also provides Pulmonary Rehabilitation and smoking cessation. All of these 
options are available to ensure the best tertiary care is provided to the veterans. 
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Implications for Nursing Care
Wewers and Crystal (2013) make a point in saying that AAT 
augmentation therapy is a triumph over a genetic disease. They go on to 
mention that it is the only genetic lung disease with effective therapy for 
all affected people (Wewers & Crystal, 2013). With this being the case; 
nurses should be advocates for testing these individuals. Detection is the 
biggest challenge health care professional’s face.
Stoller and Brantly (2013) discuss reasons for the lack of AATD detection. 
The medical and health care staff are undereducated on the subject of 
AATD. They also lack the awareness to recognize the clinical 
manifestations adequately. Some of these patients will never see a 
Pulmonologist and many primary care providers seem to lack the basic 
knowledge to assess this disease. A questionnaire regarding signs and 
symptoms of AATD was given to a group of Respiratory Therapists, as 
well as, internal medicine trainees and the average score was 53% 
(Stoller & Brantly, 2013). There is a need for education of healthcare 
professionals in identifying this disease.
The role of the Pulmonary Advanced Practice Nurse (APN) at the VAACC 
should be to educate staff. Week there is a Primary Care Provider and 
Nurse meeting at the VAACC. A presentation at these meetings, 
regarding AATD, would be prudent. Engaging with the “first line” 
providers and nurses would be a good start in educating the staff. Also, 
the Pulmonary APN would provide information to the Registered 
Respiratory Therapists (RRTs) who perform Pulmonary Function Testing 
(PFT) about AATD and ask them to inform the physicians when they 
suspect AATD. Since many of these patients are underdiagnosed; most of 
them probably don’t see a Pulmonologist. Educating RRTs would be an 
excellent way in indentifying potential AATD patients. 
Conclusion
Alpha-1 antitrypsin deficiency has many different genetic mutations. 
The most damaging of these mutations is the Z-homologous AAT 
allele. Even with this genetic mutation, it takes environmental 
exposure for COPD to occur. If detected at a younger age the patient 
would understand the risk factors associated with smoking and 
environmental exposures and could avoid COPD completely. AATD-
acquired COPD is treatable. Prolastin therapy reduces symptoms and 
lessens exacerbations. The biggest challenge with this disease is the 
lack of knowledge and under-diagnosing of AATD. Providing 
education to providers, nurses, and respiratory therapists regarding 
this very treatable lung disease is important to help these patients 
prosper. 
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